Newsroom
ARHP Members Commend the FDA for Evidence-Based Policy Making on Drospirenone
For Immediate Release
December 9, 2011
Statement by Wayne C. Shields, ARHP President & CEO
On behalf of the 12,000 reproductive health professionals represented by ARHP, I would like to commend members of the FDA advisory panel on yesterday’s wise decision to maintain the current status for contraceptive methods containing the hormone drospirenone. This decision represents an excellent example of making policy decisions based on the best scientific evidence. It can be challenging for anyone—including health professionals, educators, policymakers, and the public—to understand the concept of relative risk in general. ARHP’s position is that understanding risks associated with the use of contraceptive methods and developing the skills necessary to translate the scientific literature are essential components of high-quality reproductive health care. ARHP is committed to training providers about how to communicate effectively with their patients on this issue. It is important that women have a wide range of safe and effective contraceptive options available to them, and that they understand the risks and benefits of using their method of choice.
###
The Association of Reproductive Health Professionals (ARHP) is the leading
source for trusted medical education and information on reproductive and sexual
health. ARHP educates health care providers, informs consumers, and helps shape
public policy. ARHP is a non-profit membership association composed of highly
qualified and committed experts in reproductive health. ARHP members are health
professionals in clinical practice, education, research, and advocacy and they
include physicians, nurse practitioners, physician assistants, nurse midwives,
researchers, educators, pharmacists, and other professionals in reproductive
health. To learn more, visit: http://www.arhp.org.
|
